@article {MeschiaS50.006作者={詹姆斯Meschia和Brajesh拉尔和乔治·霍华德和加里Roubin和罗伯特·布朗和凯文·巴雷特和Seemant查图尔维迪马克Chimowitz和巴特Demaerschalk弗吉尼亚霍华德和约翰·休斯顿和罗纳德·拉扎尔和韦斯利·摩尔和克劳迪娅Moy谭雅图兰和珍妮弗Voeks和托马斯·王硕},title ={无症状的颈动脉狭窄的颈动脉血管再生和医疗管理:Crest-2 (S50.006)},体积={90}={15}补充数量,elocation-id = {S50.006} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:提供Crest-2临床试验的总结,和研究进展。首页背景:超过100000的颈动脉血管再生程序完成每年在美国无症状的颈动脉狭窄。颈动脉内膜切除手术的安全性(CEA)和颈动脉支架植入(CAS),和药物治疗的疗效改变动脉粥样硬化的进展有所改善。因此,之前的随机试验的适用性在无症状的颈动脉狭窄一直质疑目前的治疗决策。设计/方法:研究所资助的目的CREST-2是比较CEA和强化药物治疗与IMT (n = 1240),中科院和IMT与IMT (n = 1240),通过两个并行随机临床试验在大约120个医疗中心,包括与NIH-StrokeNet合作。复合主要结果是任何中风或死亡后44天内随机化或侧缺血性中风之后4年。二次结果包括认知功能,通过计算机辅助电话访谈中定期评估。IMT定向集中,包括严格控制血压(收缩压目标\ < 140 mm Hg)和胆固醇(低密度脂蛋白目标\ < 70 mg / dl)和生活方式指导。结果:10月8日,2017年,选址委员会已经批准了159个站点,其中113(71 \ %)已注册至少一个病人。外科手术和介入管理委员会370年受到信任医生和160干涉。额外的182个干涉已获批准提交额外的情况下通过CREST-2同伴注册。784名患者被随机、383(49 \ %)患者在动脉内膜切除术试验中,401(51 \ %)患者在支架试验。结论:CREST-2旨在确定无症状的颈动脉狭窄的最佳方法。将提供一个更新的数字病人随机中心认证,以及外科医生和干涉完全批准。 The CREST-2 Registry will provide the option of CAS while enhancing interventionists{\textquoteright} credentials for participation in CREST-2.Disclosure: Dr. Meschia has nothing to disclose. Dr. Lal has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Roubin has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Barrett has nothing to disclose. Dr. Chaturvedi has received personal compensation in an editorial capacity for NEJM Journal Watch Neurology. Dr. Chaturvedi has received research support from Boehringer Ingelheim. Dr. Chimowitz has nothing to disclose. Dr. Demaerschalk has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Huston has nothing to disclose. Dr. Lazar has nothing to disclose. Dr. Moore has nothing to disclose. Dr. Moy has nothing to disclose. Dr. Turan has nothing to disclose. Dr. Voeks has nothing to disclose. Dr. Brott has nothing to disclose.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/S50.006}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }